Hosted on MSN1mon
Gene Therapy Stabilizes Rare Chronic HPV Disease
For recurrent respiratory papillomatosis (RRP), novel gene therapy to jump-start immunity to the human papillomavirus (HPV) that causes it was safe and yielded complete response in many cases ...
Monthly Prescribing Reference1mon
Gene Therapy Gets Priority Review for Recurrent Respiratory Papillomatosis
for the treatment of adults with recurrent respiratory papillomatosis (RRP). RRP is a rare neoplastic disease caused by an infection with human papillomavirus (HPV) 6 or 11. It is characterized by ...
Medscape5d
Human Papillomavirus: Gene Expression, Regulation and Prospects for Novel Diagnostic Methods and Antiviral Therapies
Transcriptional regulation is important. An array of gene promoters in the human papillomavirus (HPV) early region may be actively engaged in transcription of the genome and controlled in response ...
Business Insider1mon
Precigen’s BLA for PRGN-2012 in papillomatosis granted priority review by FDA
PRGN-2012 is designed to elicit immune responses directed against cells infected with human papillomavirus, or HPV, 6 or HPV 11. PRGN-2012 received Breakthrough Therapy Designation, Orphan Drug ...
MarketWatch1mon
Precigen Gets FDA Priority Review of Recurrent Respiratory Papillomatosis Treatment
Precigen has won U.S. Food and Drug Administration priority review for its application seeking approval of its proposed PRGN-2012 gene therapy for adults with recurrent respiratory papillomatosis ...
The Business Journals1mon
Germantown biopharma is on the cusp of bringing its first product to market
The clinical-stage company, which is advancing a gene therapy to treat a rare disease called recurrent respiratory papillomatosis ... human papillomavirus, or HPV, can cause benign tumors on ...